Cannabix Technol Stock Price, News & Analysis

Cannabix Technologies is advancing its Marijuana Breathalyzer devices, notably the THC Breath Analyzer (THCBA), designed for law enforcement and workplace drug testing. The company is increasing beta testing at a high-volume clinic in the Northwestern US and has shipped units to a biomedical clinic in Ontario. The THCBA tests for recent THC use in under five minutes and is undergoing enhancements for manufacturability and performance. Preliminary discussions with North American manufacturers have commenced, with version 4.0 targeted for production by Q4 2021.

Cannabix Technologies has received a patent from the United States Patent and Trademark Office for its innovative Marijuana Breathalyzer device, designed for law enforcement and workplace applications. The patent, numbered 17/019728, enhances the company's FAIMS technology for detecting THC in breath samples. Cannabix continues to expand its intellectual property portfolio with recent patents from both the USPTO and the Canadian Intellectual Property Office. The breathalyzer aims to provide a reliable method for identifying recent marijuana use and potential impairment.

Cannabix Technologies has received patent No. 2887841 for its Marijuana Breathalyzer device, enhancing its intellectual property in cannabis detection technology. The device, aimed at law enforcement and employers, detects THC to ensure public safety. Following this, Cannabix delivered its THC Breath Analyzer for beta testing at a leading clinic in the U.S. The evolving legal landscape in states like Oregon and New Jersey presents opportunities for improved drug testing solutions. However, the company faces risks including market conditions and regulatory approval.

Cannabix Technologies is advancing its Marijuana Breathalyzer devices aimed at enhancing public safety for law enforcement and workplaces. The company will ship its THC Breath Analyzer to a Northwestern U.S. clinic for beta testing, building on earlier tests in California. Feedback on the device has been positive, noting its ease of use and quick testing capability. Cannabix is also expanding its facility in Burnaby, BC, to boost production and staffing. However, the company faces risks regarding product development and market conditions, with no current commercial sales.

Cannabix Technologies has received a notice of allowance from the USPTO for its patent application No. 17/019728. This patent focuses on FAIMS technology for marijuana breathalyzers aimed at law enforcement and workplaces. The device detects THC in breath with advanced ion mobility techniques. Additionally, Cannabix plans to beta test its THC Breath Analyzer (THCBA) at a clinic in the Northwestern U.S. in May, enhancing user experience and machine learning capabilities. The company continues to expand its intellectual property portfolio, receiving multiple allowances and grants in recent months.

Cannabix Technologies Inc. has received a notice of allowance from the Canadian Intellectual Property Office for its cannabis drug detection device patent application, No. 2887841, filed on April 16, 2015. This device aims to assist law enforcement and employers in identifying THC impairment through breath samples. However, a notice of allowance does not equate to a granted patent. The company continues to develop marijuana breathalyzer technology for workplace and law enforcement use, targeting improvements in public safety.

Cannabix Technologies Inc. is advancing its THC Breath Analyzer by commencing beta testing with a private drug testing clinic in the Northwestern United States. The prototype aims to provide a non-invasive method for detecting recent marijuana use, aligning detection with impairment. Current testing methods identify THC for extended periods, complicating impairment assessments. The Clinic, experienced in drug testing technologies, will assist in enhancing the device's functionality.

Beta tests will target machine learning database development and cross-reactivity analysis.

Cannabix Technologies has developed the latest prototype of its Marijuana Breathalyzer, designed to provide law enforcement and employers a means to test for recent THC use. The new device includes enhancements such as a sterilization module and improved breath flow analysis, yielding results in under five minutes. With growing legalization in the U.S., this innovative technology aims to address the challenges of current drug testing methods that fail to accurately identify impairment. Cannabix's breathalyzer targets immediate use detection, differentiating it from traditional tests.

Cannabix Technologies (CSE: BLO, OTC PINK: BLOZF) has announced significant advancements in its marijuana breathalyzer development. The company achieved enhanced resolving power and molecular specificity with the Cannabix FAIMS Beta 3.2 circuit, utilizing new PCB design and mosfet chip technology. Additionally, a more compact circuit board design improves device portability. The technology isolates and detects THC in breath, aiming for accurate impairment detection, especially in driving. CEO Rav Mlait emphasized the technological progress made despite COVID-19 challenges.